Current Report Filing (8-k)
November 06 2019 - 4:11PM
Edgar (US Regulatory)
0000025743
false
0000025743
2019-11-06
2019-11-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November
6, 2019
(Exact
Name of Registrant as Specified in its Charter)
Nevada
|
|
001-00100
|
|
87-0233535
|
(State
or Other
Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
951 Yamato Road, Suite 220
Boca Raton, FL 33431
|
(Address
of Principal Executive Office) (Zip Code)
|
Registrant’s
telephone number, including area code: (561) 961-1900
N/A
|
(Former
name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
Trading Symbol
|
Name of Each Exchange on Which Registered
|
Common Stock, par value $0.001 per share
|
TXMD
|
The Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item
2.02
|
Results
of Operations and Financial Condition.
|
On
November 6, 2019, TherapeuticsMD, Inc. (the "Company") issued a press release announcing its financial results for the
third quarter ended September 30, 2019. In addition, the Company will be using a slide presentation during its earnings conference
call. A copy of the press release and slide presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current
Report on Form 8-K and are incorporated herein by reference.
The
information in Item 2.02 of this Current Report on Form 8-K (including the exhibits) is furnished and shall not be deemed to be
“filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report on Form 8-K (including
the exhibits) shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities
Act”), or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation
language in the filing.
The
Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in its expectations
or any change in events, conditions, or circumstances on which any forward-looking statement is based.
|
Item
7.01
|
Regulation
FD Disclosure.
|
On
November 6, 2019, the Company issued a press release announcing the Company’s financial results for its third quarter ended
September 30, 2019. In addition, the Company will be using a slide presentation during its earnings conference call. The information
included in this Item 7.01 and in Exhibits 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18
of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
|
Exhibits
|
Exhibit
Index
|
|
|
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
Release from TherapeuticsMD, Inc., dated November 6, 2019, entitled TherapeuticsMD Announces Third Quarter 2019 Financial
Results.
|
|
99.2
|
TherapeuticsMD, Inc. Presentation dated November 6, 2019.
|
|
104
|
Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
THERAPEUTICSMD, INC.
|
|
|
Date: November 6, 2019
|
By:
|
/s/ Daniel A. Cartwright
|
|
Name:
|
Daniel A. Cartwright
|
|
Title:
|
Chief Financial Officer
|
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Sep 2023 to Sep 2024